Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease

Refaie, E; Mateo, Sandra García; Domínguez, Samuel Jesús Martínez; Gargallo-Puyuelo, C J; Quilez, Laura Lario; Carrera‐Lasfuentes, Patricia; Villarino, M.; García, Fernando L. de la Vega

doi:10.1016/j.gastrohep.2021.03.012

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pooled estimate of 63 studies 11 , 12 , 14 , 25 , 29 , 31 , 32 , 36 , 37 , 39 – 43 , 49 – 54 , 58 , 59 , 61 , 66 – 69 , 72 , 75 , 77 – 82 , 85 , 86 , 88 – 96 , 98 , 99 , 102 – 104 , 106 indicated an overall prevalence rate of 6.10% (95% CI 3.15–9.04%) of COVID-19 in patients with any IBD. Heterogeneity was very high (I 2 : 100%); hence a random effect model was used.…”

Section: Resultsmentioning

confidence: 99%

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Abdulla

Mohammed

AlQamish

et al. 2022

Sci Rep

View full text Add to dashboard Cite

There is conflicting evidence concerning the effect of inflammatory bowel disease (IBD) on COVID-19 incidence and outcome. Hence, we aimed to evaluate the published evidence through a systematic review process and perform a meta-analysis to assess the association between IBD and COVID-19. A compressive literature search was performed in PubMed/Medline, Scopus, Embase, and Cochrane Library from inception to July 2021. A snowball search in Google, Google Scholar, Research Gate, and MedRxiv; and bibliographic research were also performed to identify any other relevant articles. Quantitative observational studies such as cohort, cross-sectional, and case–control studies that assessed the incidence, risk, and outcomes of COVID-19 among the adult IBD patients published in the English language, were considered for this review. The incidence and risk of COVID-19, COVID-19 hospitalization, the severity of COVID-19, and mortality were considered as the outcomes of interest. The Joanna Briggs Institute critical appraisal checklist was used for quality assessment. A subgroup and sensitivity analysis were performed to explore the heterogeneity and robustness of the results, respectively. A total of 86 studies out of 2828 non-duplicate records were considered for this meta-analysis. The studies were single or multicentric internationally from settings such as IBD centres, medical colleges, hospitals, or from the general public. Most of the studies were observed to be of good quality with an acceptable risk of bias. The pooled prevalence of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality in the IBD population were 6.10%, 10.63%, 40.43%, and 1.94%, respectively. IBD was not significantly (p > 0.05) associated with the risk of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality. In contrast, ulcerative colitis was significantly associated with a higher risk of COVID-19 (OR 1.37; p = 0.01), COVID-19 hospitalization (OR 1.28; p < 0.00001), and severe COVID-19 (OR 2.45; p < 0.0007). Crohn’s disease was significantly associated with a lesser risk of severe COVID-19 (OR 0.48; p = 0.02). Type of IBD was a potential factor that might have contributed to the higher level of heterogeneity. There was a significant association between ulcerative colitis and increased risk of COVID-19, COVID-19 hospitalization, and severe COVID-19 infection. This association was not observed in patients with Crohns' disease or in those diagnosed non-specifically as IBD.

show abstract

Section: Resultsmentioning

confidence: 99%

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Abdulla

Mohammed

AlQamish

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Managing the psychological well-being of patients with chronic diseases has always been a clinical challenge. Given the high incidence of emotional disorders, especially in novel circumstances like the rapid COVID-19 outbreak in China, the complexity of managing these patients increased, leading to signi cant pressure and an impact on their quality of life and disease course [9].…”

Section: Introductionmentioning

confidence: 99%

Influence of the COVID-19 Outbreak on Health-Related Quality of Life in Inflammatory Bowel Disease Patients in China: A Cross-Sectional Questionnaire-Based Study

Wang,

Liu,

Fan

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Following the Chinese government's announcement that the zero-COVID policy had ended, there was a rapid and widespread outbreak of COVID-19. In this context, the condition and psychological impact on IBD patients were unknown, and prior literature lacked reports on the health-related quality of life (HRQoL) of IBD patients during large COVID-19 outbreaks in China. Therefore, our study aimed to investigate the HRQoL of IBD patients during the COVID-19 outbreak in China. Methods We employed a cross-sectional survey via web-based questionnaires. The participants were IBD patients who had previously received treatment at Nanjing BenQ Medical Center. They completed the questionnaire between January 9, 2023, and January 23, 2023. We primarily assessed the HRQoL of IBD patients using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores, and statistical analyses included the Chi-square and Mann-Whitney U tests. Results According to our survey, significant differences were observed in the following groups based on SIBDQ scores: types of IBD (p = 0.037), usage of medication after COVID-19 infection (p = 0.028), whether IBD patients felt more susceptible to COVID-19 than the general population (p < 0.05), whether their study or work had been negatively affected by COVID-19 in the past month (p < 0.05), and whether IBD patients had taken medication regularly according to medical advice within the past month (p < 0.05). Conclusions During the COVID-19 pandemic, the overall HRQoL of IBD patients was affected. Patients with ulcerative colitis (UC) exhibited higher HRQoL than those with Crohn's disease (CD). Furthermore, IBD patients who maintained a positive attitude during the epidemic experienced higher HRQoL.

show abstract

“…A systematic review evaluated twelve studies from different countries, of which seven reported a worsening in adherence in the pandemic period compared with previous years, while five studies showed no change or an improvement in adherence during the COVID-19 pandemic [4]. While most studies have focused on specific conditions, such as anxiety and depression [5] and inflammatory diseases [6,7], or on certain types of medications, such as immunosuppressive and biological therapies [8][9][10], there is still limited research on the impact of the pandemic on the general chronic outpatient population.…”

Section: Introductionmentioning

confidence: 99%

Patient-Perceived Impact of the COVID-19 Pandemic on Medication Adherence and Access to Care for Long-Term Diseases: A Cross-Sectional Online Survey

Santos,

Boulaguiem,

Baysson

et al. 2024

COVID

View full text Add to dashboard Cite

The COVID-19 pandemic has been associated with lifestyle changes, reduced access to care and potential impacts on medication self-management. Our main objectives are to evaluate the impact of the pandemic on patient adherence and access to care and long-term medications and determine its association with sociodemographic and clinical factors. This study is part of the Specchio-COVID-19 longitudinal cohort study in Geneva, Switzerland, conducted through an online questionnaire. Among the 982 participants (median age: 56; 61% female), 827 took long-term medications. There were 76 reported changes in medication dosages, of which 24 (31%) were without a physician’s recommendation, and 51 delays in initiation or premature medication interruptions, of which 24 (47%) were without a physician’s recommendation. Only 1% (9/827) of participants faced medication access issues. Participants taking a respiratory medication had a four-times greater odds of reporting more regular medication (OR = 4.27; CI 95%: 2.11–8.63) intake, whereas each year increase in age was significantly associated with 6% fewer relative risks of discontinuation (OR = 0.94; CI 95%: 0.91–0.97) and 3% fewer relative risks of changes in medication dosage (OR = 0.97; CI 95%: 0.95–1.00). Despite the limited impact of the pandemic on adherence and access to medications, our results emphasize the need for understanding patient challenges when self-managing their long-term medication, notably during public health crises.

show abstract

Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease

Cited by 4 publications

References 31 publications

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Influence of the COVID-19 Outbreak on Health-Related Quality of Life in Inflammatory Bowel Disease Patients in China: A Cross-Sectional Questionnaire-Based Study

Patient-Perceived Impact of the COVID-19 Pandemic on Medication Adherence and Access to Care for Long-Term Diseases: A Cross-Sectional Online Survey

Contact Info

Product

Resources

About